O002 - GLUCOSAFE 2 - A NEW DECISION-SUPPORT SYSTEM FOR BLOOD GLUCOSE MANAGEMENT AND NUTRITION THERAPY: ITS IMPACT ON NUTRITION FOR CRITICALLY ILL PATIENTS

O002

GLUCOSAFE 2 - A NEW DECISION-SUPPORT SYSTEM FOR BLOOD GLUCOSE MANAGEMENT AND NUTRITION THERAPY: ITS IMPACT ON NUTRITION FOR CRITICALLY ILL PATIENTS

A. De Watteville^1,2,3,*, U. Pielmeier⁴, E. Balzani⁵, H. Wozniak^1,6, S. Primmaz^1,6, L. Quagliara^1,3, S. Andreassen⁴, C. P. Heidegger^1,6

¹Division of Intensive Care, Department of Acute Care Medicine, ²Clinical Nutrition, Division of Gastroenterology, Hepatology & Nutrition , ³Care Directorate, Geneva University Hospitals , Geneva, Switzerland, ⁴Department of Health Science and Technology, The Faculty of Medicine, CardioTech, Aalborg University, Aalborg, Denmark, ⁵Interdepartimental Center of Medical Sciences, University of Trento, Trento, Italy, ⁶Department of anaesthesiology, pharmacology, intensive care and emergency medicine, Geneva University Hospitals , Geneva, Switzerland

Rationale: Providing optimal management of insulin and nutrition therapy for critically ill patients is a major challenge due to dynamic metabolic changes. Glucosafe 2 (GS2) is an innovative, model-based decision support system designed to predict insulin sensitivity from clinical and metabolic data, supporting blood glucose (BG) control and enabling personalized nutrition therapy in critically ill patients. Analysis focuses on the impact of GS2 on the achievement of nutrition targets.

Methods: This randomized controlled study included 142 adult ICU patients at Geneva University Hospitals, randomized to GS2-guided care (n=71) or standard care (n=71) for up to 15 days. Targets were progressively increased over the first 3 days and subsequently guided by indirect calorimetry or predictive equations. Data are presented as medians, and between-group comparisons were performed using the Wilcoxon rank-sum test.

Results: Protein intake tended to be higher in the GS2 group compared with standard care (57.1 vs. 48.1 g/day, p = 0.058). Protein target achievement was significantly greater in the GS2 group (66% vs. 56%, p=0.044). A higher proportion of GS2 patients reached ≥80% of protein targets (30% vs. 23%), without reaching statistical significance. Median daily energy intake (1337 vs. 1203 kcal/day, p=0.061) did not differ significantly between groups, although prescribed energy targets were higher in the GS2 group (1715 vs. 1652 kcal/day, p=0.027). Energy target achievement was similar between groups (73% vs. 73%, p=0.488), as was the proportion of patients reaching ≥80% of targets (38% vs. 41%, p=0.864).

Conclusion: GS2 supports personalized nutritional therapy alongside blood glucose management for ICU patients and helps to meet protein targets without compromising energy intake. These findings highlight GS2’s potential to improve nutritional adequacy.

Disclosure of Interest: None declared